Idiopathic pulmonary fibrosis

ipf · society: ATS/ERS/JRS/ALAT

← back to Pulmonary & Critical Care

Summary

2022 ATS/ERS/JRS/ALAT guideline updates IPF diagnosis and management and introduces the new entity of progressive pulmonary fibrosis (PPF) in non-IPF fibrotic ILD. Key updates: transbronchial lung cryobiopsy (TBLC) is now an acceptable alternative to surgical lung biopsy in experienced centers; conditional recommendations against antacid medication and antireflux surgery for the sole purpose of improving respiratory outcomes in IPF; no recommendation on genomic classifier testing. PPF is defined by ≥2 of 3 criteria (symptoms, physiologic decline, radiologic progression) within 1 year, and nintedanib is conditionally recommended for PPF after failure of standard ILD-directed therapy, while pirfenidone requires further research.

Current guideline: 2022 ATS/ERS/JRS/ALAT IPF Guideline · download Anki sub-deck

Versions

Table of contents